



LEGISLATIVE FISCAL OFFICE
Fiscal Note

Fiscal Note On: **HB 370** HLS 19RS 425

Bill Text Version: **REENGROSSED**

Opp. Chamb. Action: **W/ SEN FLOOR AMD**

Proposed Amd.:

Sub. Bill For.:

Date: June 3, 2019	10:41 AM	Author: STOKES
Dept./Agy.: LA Dept. of Insurance/Office of Group Benefits		
Subject: Drug Benefits for Persons with Metastatic Cancer		Analyst: Zachary Rau

INSURANCE/HEALTH

REF SEE FISC NOTE SG EX

Page 1 of 1

Provides relative to prescription drug benefits for persons with stage-four advanced, metastatic cancer

Proposed law states that not health coverage plan in LA may use step therapy or fail first protocols to restrict prescription benefits for the treatment of stage-four, metastatic cancer or associated conditions if one of the following applies: the prescribed drug/drug regimen has approved indication from the US Food & Drug Administration (FDA); the prescribed drug/drug regimen has approved indicated from the National Comprehensive Cancer Network Drugs and Biologics Compendium; or if the the prescribed drug/drug regimen is supported by peer-reviewed, evidence-based literature. Proposed law shall not apply if the preferred drug/drug regimen is considered a clinical equivalent, contains identical active ingredient(s), and is proven to have the same efficacy. Proposed law requires notification by providers to health insurers when prescribing drugs for conditions associated with stage-four, metastatic cancer when requesting authorization. Proposed law defines "health coverage plan" to include plans subject to provisions of proposed law that are administered by a pharmacy benefit manager. Effective upon governor's signature.

EXPENDITURES	2019-20	2020-21	2021-22	2022-23	2023-24	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	\$0
Agy. Self-Gen.	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	\$0	\$0	\$0	\$0	\$0	\$0
Annual Total						

REVENUES	2019-20	2020-21	2021-22	2022-23	2023-24	5 -YEAR TOTAL
State Gen. Fd.	\$0	\$0	\$0	\$0	\$0	\$0
Agy. Self-Gen.	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	SEE BELOW	
Ded./Other	\$0	\$0	\$0	\$0	\$0	\$0
Federal Funds	\$0	\$0	\$0	\$0	\$0	\$0
Local Funds	\$0	\$0	\$0	\$0	\$0	\$0
Annual Total						

EXPENDITURE EXPLANATION

The Office of Group Benefits reports that the proposed legislation as written will result in minimal or no expenditure impact based upon its current drug formulary makeup. Furthermore, the LA Dept. of Insurance reports that proposed law will have a negligible effect on the private insurance market, as the majority of costs would be in the few cases where patents have expired on certain drugs and private insurers are unable to steer patients to use more affordable generic drugs with equal or better efficacy rather than using name-brand drugs.

REVENUE EXPLANATION

There is no anticipated direct material effect on governmental revenues as a result of this measure.

Senate	Dual Referral Rules	House	<i>Evan Brasseaux</i>
<input checked="" type="checkbox"/> 13.5.1 >= \$100,000 Annual Fiscal Cost {S & H}		<input checked="" type="checkbox"/> 6.8(F)(1) >= \$100,000 SGF Fiscal Cost {H & S}	Evan Brasseaux
<input type="checkbox"/> 13.5.2 >= \$500,000 Annual Tax or Fee Change {S & H}		<input type="checkbox"/> 6.8(G) >= \$500,000 Tax or Fee Increase or a Net Fee Decrease {S}	Staff Director